ロード中...

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells

Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision...

詳細記述

保存先:
書誌詳細
主要な著者: Cheng, Haiying, Zhang, Zhenfeng, Borczuk, Alain, Powell, Charles A., Balajee, Adayabalam S., Lieberman, Howard B., Halmos, Balazs
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2013
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616665/
https://ncbi.nlm.nih.gov/pubmed/23275151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgs393
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!